| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084253288 |
| P356 | DOI | 10.1186/S40880-017-0198-3 |
| P932 | PMC publication ID | 5351274 |
| P698 | PubMed publication ID | 28292326 |
| P50 | author | Jian Zhang | Q95001421 |
| P2093 | author name string | Yi Lu | |
| Evan T Keller | |||
| Jinlu Dai | |||
| Laurie K McCauley | |||
| Hernan Roca | |||
| Jill M Keller | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells | Q24317507 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines | Q28139004 | ||
| Identification of a factor that links apoptotic cells to phagocytes | Q28217034 | ||
| Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation | Q28575953 | ||
| The role of myeloid cells in the promotion of tumour angiogenesis | Q29614299 | ||
| The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers | Q30992805 | ||
| Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases | Q33293423 | ||
| Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer | Q33389676 | ||
| CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization | Q33553562 | ||
| Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. | Q33611312 | ||
| In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice | Q33837085 | ||
| Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. | Q33958982 | ||
| Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
| The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression | Q39956710 | ||
| RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes | Q40050213 | ||
| CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients | Q40212457 | ||
| Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice | Q40304139 | ||
| Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. | Q40742643 | ||
| Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice | Q40801056 | ||
| Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCAP: role of interleukin-6. | Q41083320 | ||
| Immunologic aspects of osteoporosis | Q41700884 | ||
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 | ||
| Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing | Q41953761 | ||
| Weaning-induced expression of a milk-fat globule protein, MFG-E8, in mouse mammary glands, as demonstrated by the analyses of its mRNA, protein and phosphatidylserine-binding activity | Q42156178 | ||
| Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. | Q42482513 | ||
| Osteoprotegerin and rank ligand expression in prostate cancer | Q42502915 | ||
| What do we mean when we write "senescence," "apoptosis," "necrosis," or "clearance of dying cells"? | Q42854358 | ||
| Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma | Q44220344 | ||
| Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells | Q45874119 | ||
| The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. | Q46365760 | ||
| RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model | Q46715452 | ||
| Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer | Q46748260 | ||
| Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway | Q47398934 | ||
| In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer | Q47816427 | ||
| Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis | Q34107357 | ||
| Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond | Q34366449 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 | ||
| CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer | Q34585720 | ||
| Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. | Q34708745 | ||
| The first Tianjin, China forum on tumor microenvironment | Q34786304 | ||
| IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. | Q35037290 | ||
| Roles of bone marrow cells in skeletal metastases: no longer bystanders | Q35603122 | ||
| Crosstalk between cancer cells and bone microenvironment in bone metastasis | Q36032072 | ||
| Interleukin-6 regulation of prostate cancer cell growth | Q36101905 | ||
| Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. | Q36278280 | ||
| Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy | Q36378276 | ||
| Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction | Q36476085 | ||
| Osteocyte control of osteoclastogenesis | Q36514172 | ||
| Bone marrow macrophages support prostate cancer growth in bone | Q36546464 | ||
| A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China | Q36836736 | ||
| Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality | Q37155349 | ||
| Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages | Q37199013 | ||
| A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. | Q37233535 | ||
| Inflammation and prostate cancer. | Q37298650 | ||
| Differentiation and heterogeneity in the mononuclear phagocyte system | Q37349749 | ||
| Stroma-epithelium crosstalk in prostate cancer | Q37355741 | ||
| Macrophage cathepsin K promotes prostate tumor progression in bone | Q37554550 | ||
| Biology and clinical observations of regulatory T cells in cancer immunology | Q37761674 | ||
| TAM receptor signaling and autoimmune disease | Q37804572 | ||
| Denosumab: in cancer treatment-induced bone loss | Q37806196 | ||
| Infection, inflammation and prostate carcinogenesis | Q37852301 | ||
| Interleukin-6: a multifunctional targetable cytokine in human prostate cancer | Q37888027 | ||
| Review: milk fat globule-EGF factor 8 expression, function and plausible signal transduction in resolving inflammation | Q37929022 | ||
| Th17 Cells in Protection from Tumor or Promotion of Tumor Progression | Q38907336 | ||
| Regulatory T cells: balancing protection versus pathology | Q38920427 | ||
| Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop | Q39581495 | ||
| The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma | Q39847976 | ||
| Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. | Q39905772 | ||
| Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. | Q51803777 | ||
| LuCaP 35: A new model of prostate cancer progression to androgen independence | Q52832790 | ||
| Peritoneal macrophages are distinct from monocytes and adherent macrophages. | Q53214170 | ||
| Pretreatment frequency of circulating IL-17+CD4+T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients | Q56986771 | ||
| Prognostic value of IL-6 in localized prostatic cancer | Q61197642 | ||
| Expression of osteoclast differentiation signals by stromal elements of giant cell tumors | Q73711524 | ||
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| Osteoprotegerin diminishes advanced bone cancer pain | Q73893976 | ||
| Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival | Q74153839 | ||
| Characterization of the role of IL-6 in the progression of prostate cancer | Q74587530 | ||
| Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone | Q79317200 | ||
| Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer | Q80224497 | ||
| Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma | Q80954384 | ||
| Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer | Q82278667 | ||
| Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice | Q84925181 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| tumor microenvironment | Q1786433 | ||
| prostate neoplasm | Q56014511 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 29 | |
| P577 | publication date | 2017-03-14 | |
| P1433 | published in | Chinese Journal of Cancer | Q15760211 |
| P1476 | title | Immune mediators in the tumor microenvironment of prostate cancer | |
| P478 | volume | 36 |
| Q64253447 | A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges |
| Q90216342 | CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer |
| Q42367488 | Cancer metastasis: issues and challenges |
| Q90070057 | Mass cytometry reveals species-specific differences and a new level of complexity for immune cells in the prostate |
| Q94564120 | Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Breast Cancer: A Propensity Score-Matching Study |
| Q41152020 | Prognostic value of systemic immune-inflammation index in patients with gastric cancer |
| Q48333900 | Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. |
Search more.